Sugi Predict

Sugi Predict / Targets / GCG

GCG

Pro-glucagon · P01275 · GCG on Sugi Atlas →

6,906 patent compounds predicted against GCG, 3,396 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL718112 SCHEMBL718112 0.64 19/20
SCHEMBL717956 SCHEMBL717956 0.63 19/20
SCHEMBL719431 SCHEMBL719431 0.58 19/20
SCHEMBL720019 SCHEMBL720019 0.55 19/20
SCHEMBL719447 SCHEMBL719447 0.50 19/20
SCHEMBL718235 SCHEMBL718235 0.68 18/20
SCHEMBL718792 SCHEMBL718792 0.66 18/20
SCHEMBL719527 SCHEMBL719527 0.66 18/20
SCHEMBL718899 SCHEMBL718899 0.55 18/20
SCHEMBL717624 SCHEMBL717624 0.54 18/20
SCHEMBL720851 SCHEMBL720851 0.54 18/20
SCHEMBL717134 SCHEMBL717134 0.54 18/20
SCHEMBL718572 SCHEMBL718572 0.54 18/20
SCHEMBL720404 SCHEMBL720404 0.54 18/20
SCHEMBL721126 SCHEMBL721126 0.53 18/20
SCHEMBL716732 SCHEMBL716732 0.52 18/20
SCHEMBL718106 SCHEMBL718106 0.52 18/20
SCHEMBL719249 SCHEMBL719249 0.52 18/20
SCHEMBL716260 SCHEMBL716260 0.51 18/20
SCHEMBL719380 SCHEMBL719380 0.51 18/20

Clinical trials — most relevant to GCG by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Incretins in Impaired Fasting Glucose PHASE4COMPLETED
A Research Study of VCT220 in Adult Chinese Participants With Obesity PHASE3ACTIVE_NOT_RECRUITING
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects PHASE3RECRUITING
Evaluate the Immunogenicity of a Novel Glucagon Formulation PHASE3COMPLETED
UBT251 Injection Phase II Clinical Study (CKD) PHASE2RECRUITING
A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System PHASE2WITHDRAWN
GLP-1 RA for Stage 1 Type 1 Diabetes PHASE2NOT_YET_RECRUITING
Low dosE GlibENclamide in Diabetes Part A PHASE2COMPLETED
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia PHASE2COMPLETED
Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories) PHASE1COMPLETED
Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus PHASE1COMPLETED
Incretin Regulation of Insulin Secretion in Monogenic Diabetes PHASE1COMPLETED
A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus PHASE1COMPLETED
Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration PHASE1COMPLETED
Graded Insulin Suppression Test P&F PHASE1RECRUITING
Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism EARLY_PHASE1COMPLETED
Long-term Health After Severe Acute Malnutrition in Children and Adults: the Role of the Pancreas nanCOMPLETED
Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants nanCOMPLETED
The Effect of Dietary Fiber-enriched Cereals on Glycemic Control and Secretion of Gut Hormones nanCOMPLETED
Influence of DPP-4 on Inflammatory Parameters in Diabetics: Gender Aspects nanUNKNOWN
Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone? nanCOMPLETED
Clinical Assessment of a Closed-loop System With Glucagon, Exercise and Mixed Meals nanCOMPLETED
Hepatic Metabolic Changes in Response to Glucagon Infusion nanCOMPLETED
GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake nanCOMPLETED
MINI Bypass Versus Roux-en-Y Bypass: Differences in HOrmonal Secretions at 2 Years of Surgery nanCOMPLETED
The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion nanCOMPLETED
The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors nanCOMPLETED
Incretin Hormones in Type-1 Diabetes Mellitus Glycemic Response in Type-1 Diabetes Mellitus nanCOMPLETED
Adequate Hydration and Health Outcomes nanRECRUITING
The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a GCG binder may also engage these)

ProteinNameSimilarity
P05110 — 1.000 P05110 →
P06883 — 1.000 P06883 →
P01273 — 1.000 P01273 →
P68259 — 1.000 P68259 →
P29794 — 0.998 P29794 →
P55095 — 0.998 P55095 →
P22890 — 0.998 P22890 →
Q9PUR0 — 0.998 Q9PUR0 →
P01274 — 0.997 P01274 →
Q8MJ25 — 0.996 Q8MJ25 →
P01272 — 0.996 P01272 →
O12956 — 0.996 O12956 →
Q91189 — 0.994 Q91189 →
P41585 — 0.994 P41585 →
P04204 — 0.993 P04204 →
Q9PUR1 — 0.993 Q9PUR1 →
Q1MX22 — 0.991 Q1MX22 →
P81401 — 0.989 P81401 →
A8WU84 — 0.989 A8WU84 →
P79695 — 0.989 P79695 →
P04092 — 0.989 P04092 →
P21786 — 0.989 P21786 →
P01283 — 0.988 P01283 →
Q9PT99 — 0.988 Q9PT99 →
O70176 — 0.988 O70176 →
P32648 — 0.988 P32648 →
Q9XW71 — 0.988 Q9XW71 →
O96690 — 0.987 O96690 →
Q91971 — 0.987 Q91971 →
Q9I8P2 — 0.987 Q9I8P2 →